Reading the quarterly, I tend to get the feeling that the company is still plugging away developing the bigger picture in the background. A picture for sustaining high end profit margins and little competition in the ultra fine end of the graphite spectrum.
University projects have changed over the past 15 years. Gone are the days when universities just sucked all government money. Now they have to generate revenue and have business models, and those with R+D projects, tend to push boundaries in medicine and sciences more and more. I think we are seeing this with AXEs move to align with product development.
I do expect more announcements this year regarding end user interest as purity is gained, because basically AXE are taking out the refining processes that companies will have to do when they buy from other graphite producers.
Sadly not a short term investment, but a good one to put away and watch as the graphite market evolves.
- Forums
- ASX - By Stock
- AXE
- q out early - why?
q out early - why?, page-13
Featured News
Add AXE (ASX) to my watchlist
(20min delay)
|
|||||
Last
36.0¢ |
Change
-0.020(5.26%) |
Mkt cap ! $91.74M |
Open | High | Low | Value | Volume |
39.5¢ | 39.5¢ | 35.5¢ | $186.8K | 508.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 39610 | 35.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 7888 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 39610 | 0.355 |
9 | 79399 | 0.350 |
1 | 11000 | 0.345 |
4 | 111450 | 0.340 |
5 | 50350 | 0.335 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 7888 | 1 |
0.390 | 51464 | 4 |
0.395 | 50496 | 3 |
0.400 | 138658 | 6 |
0.405 | 176582 | 1 |
Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
Featured News
AXE (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
SPONSORED BY The Market Online